Fred Hutchinson Cancer Research Center Initiates Studies on ImmuneRegen BioSciences, Inc.'s Cancer Therapy Candidate

SCOTTSDALE, AZ--(Marketwire - February 10, 2010) - ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced the execution of an agreement with Fred Hutchinson Cancer Research Center to commence studies utilizing ImmuneRegen's Homspera. Under the agreement the Hutchinson Center will perform exploratory studies on Homspera, specifically focusing on the area of cancer immunotherapy. The Center expects to raise approximately $30 million within the next 3-4 years to support immunotherapy research projects and has recently announced a gift of approximately one-third of that amount. Studies at the Hutchinson Center will be performed under the direction of Dr. Cassian Yee , who has successfully used immune cells from patients with melanoma to cause long-term remission in their tumors.

Recent studies have found Homspera to be effective in enhancing the efficacy of a novel cancer vaccine, and previous studies have revealed anti-tumor effects. These experiments taking place at the Hutchinson Center are designed to expand on this previous research, which has identified a critical role for Homspera in directing the immune system towards fighting cancers -- in particular, aggressive cancers where conventional therapies are ineffective. This work will evaluate the effect of Homspera exposure on patients' own cancer-specific cytotoxic T-cell stimulation. While these initial studies will evaluate melanoma immunotherapy this model also has clinical relevance for a wide-range of cancer types.

"We are excited to be pursuing this relationship, which offers ImmuneRegen the opportunity to have Homspera further evaluated in the area of melanoma by a group with enormous proven expertise. Additionally, following successful findings, we would be situated perfectly to leverage our relationship with research and clinical experts at this leading Cancer Research Center who have experience in developing therapies that translate to real world cancer treatments. This could lead to a more rapid developmental path for Homspera as well," said Hal Siegel, Ph.D., ImmuneRegen's Chief Scientific Officer.

About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera®. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Homspera is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential use and scientific results for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-Q for the three months ended September 30, 2009 as filed with the Securities and Exchange Commission and report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.


Contact:
Michael K. Wilhelm
email:
Email Contact
John Fermanis
email:
Email Contact
ImmuneRegen BioSciences Inc.
Phone: 480-922-3926

Back to news